Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma

BACKGROUND: We have previously shown that podocalyxin-like protein (PODXL) is a prognostic biomarker for poor survival in gastric and esophageal adenocarcinoma treated with surgery up-front. The aim of the present study was to assess PODXL expression in tumors from patients treated with neoadjuvant ...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Transl Med
Auteurs principaux: Borg, David, Larsson, Anna H., Hedner, Charlotta, Nodin, Björn, Johnsson, Anders, Jirström, Karin
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2018
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201481/
https://ncbi.nlm.nih.gov/pubmed/30355278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-018-1668-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires